Top

Published in:

Open Access 01-12-2011 | Case report

Rosiglitazone as an option for patients with acromegaly: a case series

Authors: Héctor E Tamez-Pérez, Ana Bahena-García, María D Gómez de Ossio, Hugo Gutiérrez-Hermosillo, Alejandra L Tamez-Peña

Published in: Journal of Medical Case Reports | Issue 1/2011

Abstract

Introduction

In the patient with acromegaly, pituitary surgery is the therapeutic standard. Despite undergoing surgery, a significant number of patients with acromegaly continue to have uncontrolled growth hormone secretion. These patients require other treatments such as external irradiation and/or drug therapy.

Case presentation

We present the clinical and laboratory responses to six months of treatment with rosiglitazone in four cases. In all four cases, the patients had persistent growth hormone overproduction despite previous surgical treatment and other conventional therapy. Case 1 is a 57-year-old Caucasian woman, case 2 is a 51-year-old Hispanic man, case 3 is a 32-year-old Hispanic woman, and case 4 is a 36-year-old Hispanic man. In three of these patients, basal and nadir growth hormone and insulin-like growth factor 1 levels were significantly decreased (P < 0.05 and P < 0.01, respectively).

Conclusion

Rosiglitazone could be a treatment option in select patients with acromegaly.

Melmed S: Medical progress: acromegaly. N Engl J Med. 2006, 355: 2558-2573. 10.1056/NEJMra062453.CrossRefPubMed

Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A, Acromegaly Consensus Group: Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009, 94: 1509-1517. 10.1210/jc.2008-2421.CrossRefPubMed

Besser GM, Burman P, Daly AF: Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol. 2005, 153: 187-193. 10.1530/eje.1.01968.CrossRefPubMed

Grardišer M, Matovinović M, Vrkljan M: Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features alter rosiglitazone treatment of type 2 diabetes mellitus in a patient with acromegaly. Croat Med J. 2007, 48: 87-91.

Bastemir M, Akin F, Yaylali GF: The PPAR-γ activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly. Neuroendocrinology. 2007, 86: 119-123. 10.1159/000106830.CrossRefPubMed

Winczyk K, Kunert-Radek J, Gruszka A, Radek M, Ławnicka H, Pawlikowski M: Effects of rosiglitazone-peroxisome proliferator-activated receptor γ (PPARγ) agonist on cell viability of human pituitary adenomas in vitro. Neuro Endocrinol Lett. 2009, 30: 107-110.PubMed

Magenta G, Borenstein X, Rolando R, Jasnis MA: Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3. BMC Cancer. 2008, 8: 47-10.1186/1471-2407-8-47.CrossRefPubMedPubMedCentral

Castinetti F, Morange I, Dubois N, Albarel F, Conte-Devolx B, Dufour H, Brue T: Does first-line surgery still have its place in the treatment of acromegaly?. Ann Endocrinol (Paris). 2009, 70: 107-112.CrossRef

Emery MN, Leontiou C, Bonner SE, Merulli C, Nanzer AM, Musat M, Galloway M, Powell M, Nikookam K, Korbonits M, Grossman AB: PPAR-γ expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-γ receptor. Clin Endocrinol (Oxf). 2006, 65: 389-395. 10.1111/j.1365-2265.2006.02610.x.CrossRef

10.

Heaney AP: Novel pituitary ligands: peroxisome proliferator activating receptor-γ. Pituitary. 2003, 6: 153-159.CrossRefPubMed

11.

Heaney AP, Fernando M, Melmed S: PPAR-γ receptor ligands: novel therapy for pituitary adenomas. J Clin Invest. 2003, 111: 1381-1388.CrossRefPubMedPubMedCentral

12.

Morcos M, Fohr B, Tafel J, Pfisterer F, Hamann A, Humpert P, Bode H, Schwenger V, Zeier M, Becker C, Kasperk C, Schilling T, Hammes HP, Bierhaus A, Nawroth PP: Long-term treatment of central Cushing's syndrome with rosiglitazone. Exp Clin Endocrinol Diabetes. 2007, 115: 292-297. 10.1055/s-2007-970162.CrossRefPubMed

13.

Wajchenberg BL: β-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007, 28: 187-218.CrossRefPubMed

Title: Rosiglitazone as an option for patients with acromegaly: a case series
Authors: Héctor E Tamez-Pérez
Ana Bahena-García
María D Gómez de Ossio
Hugo Gutiérrez-Hermosillo
Alejandra L Tamez-Peña
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Journal of Medical Case Reports / Issue 1/2011
Electronic ISSN: 1752-1947
DOI: https://doi.org/10.1186/1752-1947-5-200

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Rosiglitazone as an option for patients with acromegaly: a case series

Abstract

Introduction

Case presentation

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2011

Complications arising from a misdiagnosed giant lipoma of the hand and palm: a case report

Abiotrophia defectiva knee prosthesis infection: A case report

Fish bone foreign body presenting with an acute fulminating retropharyngeal abscess in a resource-challenged center: a case report

Adhesions due to peritoneal carcinomatosis caused by a renal carcinoma leading to mechanical gastric outlet obstruction: a case report

Adult colocolic intussusception diagnosed by ultrasonography: a case report

Thyroid-stimulating hormone elevation misdiagnosed as subclinical hypothyroidism following non-convulsive status epilepticus: a case report